Kilambi News
Friday, November 20, 2026

Life sciences also notable: Boltz raises $110 million, Lilly posts mevidalen data

Life Sciences Thursday, November 19, 2026 - Updated Nov 19, 2026 07:11

AI drug design startup Boltz raised a $110 million Series A led by Bessemer less than a year after its $28 million seed, and Lilly's full Phase 2 data at CTAD showed its dopamine drug mevidalen missed its Alzheimer's endpoint by a wide margin.

Why it matters: Boltz is selling molecular design by the token to six of the twenty largest drugmakers, while the mevidalen poster closes the book on a mechanism Lilly has now failed with in two diseases.

Data as of Boltz round announced November 18, 2026; Endpoints News first reported it and its article is paywalled, so the figures here are from FirstWord Pharma and Tech.eu reporting of the same announcement, with investor detail from Bessemer Venture Partners. Mevidalen data from the PRESENCE-ALZ poster at the CTAD conference, reported in detail by NeurologyLive; Lilly removed the programme from its pipeline on October 29, 2026.

Boltz raises $110 million to sell drug design by the token. Boltz, the MIT spinout now based in London, has raised a $110 million Series A led by Bessemer Venture Partners, with existing backers Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures, and new investors Greycroft, F-Prime Capital, Hummingbird and Benchling. The round comes less than a year after a $28 million seed. Boltz says paying customers’ molecular token usage has risen 50-fold since June, when it launched its first proprietary models, BoltzMol-1 for small-molecule discovery and BoltzProt-1 for protein design, and that it has partnerships with six of the twenty largest drugmakers, including Pfizer, GSK, Takeda and Bristol Myers Squibb. The company employs about 40 AI researchers in London. No valuation was disclosed.

Lilly’s mevidalen data show a clear miss. Full results from the Phase 2 PRESENCE-ALZ trial, presented as a poster at the CTAD conference, show Eli Lilly’s dopamine D1 receptor modulator mevidalen failed its primary endpoint in 304 patients with mild-to-moderate Alzheimer’s disease in the United States and Japan. The trial required a greater than 60 percent posterior probability that either dose produced at least a 2-point benefit over placebo on the Integrated Alzheimer’s Disease Rating Scale at 24 weeks; the probabilities came in at 14.0 percent for the 25 mg dose and 21.2 percent for 50 mg, with least-squares mean differences of 0.62 and 0.95 points. Adverse event rates were similar across arms, at about 65 percent, though systolic blood pressure rose roughly 8 to 11 mm Hg after dosing. Lilly had already removed the Alzheimer’s programme from its pipeline in its third-quarter update on October 29, saying it did not meet the company’s internal bar; the drug previously missed in Lewy body dementia in 2021.

Sources

  1. Boltz bags $110M amid pharma's growing appetite for molecular AI - FirstWord Pharma - 2026-11-18
  2. London-based Boltz raises $110M Series A - Tech.eu - 2026-11-19
  3. Mevidalen misses primary endpoint in Phase 2 Alzheimer trial - NeurologyLive - 2026-11-18